Last reviewed · How we verify
NCT05859009
Primary Prevention of Gastric Varices Bleed
NA trial testing EUS-Guided Therapy of Glue and Coil in Gastric Varices Bleeding. Withdrawn.
1 July 2025
Quick facts
| Lead sponsor | Unity Health Toronto |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | factorial |
| Masking | none |
| Primary purpose | prevention |
| Start date | 1 July 2023 |
| Primary completion | 1 July 2025 |
| Estimated completion | 1 July 2026 |
Drugs / interventions tested
- EUS-Guided Therapy of Glue and Coil
- Non-Selective Beta Blockers (Propanolol) — full drug profile →
Conditions studied
- Gastric Varices Bleeding — all drugs for Gastric Varices Bleeding →
- Endoscopic Ultrasound — all drugs for Endoscopic Ultrasound →
Sponsor
Unity Health Toronto — full company profile →
Who can join
Adults 18 to 75, any sex, with Gastric Varices Bleeding or Endoscopic Ultrasound. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Primary prophylaxis of gastric varices is an important area of research, as gastric varices are a common complication of cirrhosis of the liver. Cirrhosis is a condition in which the liver becomes scarred and loses its ability to function properly, and it is a leading cause of morbidity and mortality worldwide. Gastric varices occur in up to 30% of patients with cirrhosis, and they can rupture, leading to life-threatening bleeding. The clinical, epidemiological, and public health context of primary prophylaxis of gastric varices is therefore the need to prevent the development of this complication in patients at risk for cirrhosis and to reduce the associated morbidity and mortality. The clinical trials on primary prophylaxis of gastric varices are therefore focused on evaluating the safety and efficacy of various interventions, such as beta-blockers and endoscopic techniques, in reducing the risk of gastric varices in patients with cirrhosis. The goal of this trial is to find the most effective and safe strategies for primary prophylaxis of gastric varices, in order to improve the outcomes for patients with cirrhosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05859009
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastric Varices Bleeding
Currently open trials in the same condition.
- NCT06670157 — Detachable Clip-assisted Endoscopic Cyanoacrylate Injection in the Treatment of Gastric Varices · NA · recruiting
Other Unity Health Toronto trials
Trials by the same sponsor.
- NCT07507409 — Innovative Sternal Closure Techniques: Evaluating STRATAFIX™ and DERMABOND™ for Reduced Complications in CABG Patients · Phase 4 · not yet recruiting
- NCT07455487 — First Appendectomy Using Revolve Surgical Robotic Arm · NA · not yet recruiting
- NCT07301632 — Ecstasy to Alleviate SEvere Chronic Neuropathic Pain Trial · Phase 2 · recruiting
- NCT07314905 — Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp) · Phase 3 · not yet recruiting
- NCT06571916 — Brief Skills for Safer Living (Brief-SfSL) · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05859009 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Unity Health Toronto
- Last refreshed: 14 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05859009.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing